Phase 2 Myeloma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People diagnosed with acute myelogenous leukemia (AML) where initial treatment did not work, where the disease has come back, or where the disease has features that make relapse more likely (such as certain genetic changes or signs of remaining cancer cells)
• People diagnosed with myelodysplastic syndrome (MDS) — either occurring on its own or after prior cancer treatment — including those with higher-risk disease, dependence on blood transfusions, disease that has not responded to standard treatments, or certain abnormal genetic features
• People diagnosed with acute lymphoblastic leukemia (ALL) where initial treatment did not work, where the disease has returned, or where high-risk features are present (such as certain genetic changes or signs of remaining cancer cells)
• People diagnosed with Non-Hodgkin's lymphoma (NHL) that has returned or is in a second or third remission, including after a prior stem cell transplant, where no treatments known to be curative are available
• People diagnosed with small lymphocytic lymphoma (SLL) or chronic lymphocytic leukemia (CLL) whose disease has continued to progress after at least two standard treatment courses
• People diagnosed with chronic myeloid leukemia (CML) that is in a second chronic phase or has moved into an accelerated phase
• People diagnosed with Hodgkin's disease (HD) where initial treatment did not work, where the disease has returned, or where active disease is present
• People diagnosed with stage II or III multiple myeloma that is causing symptoms and requires treatment
• A backup source of stem cells (such as a family member donor or cord blood unit) must be identified before joining
• People aged 15 to 45 years old may be considered for the higher-intensity treatment regimen (confirm with trial site)
• People aged 15 to 80 years old may be considered for the lower-intensity or reduced-intensity treatment regimens, at the discretion of the trial doctors
• People with a physical performance level of at least 60% on the Karnofsky scale (a standard medical measure of overall physical functioning)
• People whose heart pumps at least 40% of its normal capacity (for the higher-intensity and reduced-intensity regimens) or at least 30% (for the lower-intensity regimen)
• People whose lungs are functioning at least 50% of the predicted level (for the higher-intensity and reduced-intensity regimens)
• People whose kidneys are functioning well enough, with a filtration rate above 40 mL/min/1.73m² (confirm with trial site)
• People whose liver enzyme and bilirubin levels are within acceptable ranges, varying depending on which treatment regimen is being considered (confirm with trial site)
• Women who could become pregnant must have a negative pregnancy test before joining

Who may not be able to join:

• People who test positive for HIV (tested using a specific type of genetic test)
• People with a serious uncontrolled medical condition, such as a severe ongoing infection not responding to antibiotics, severe heart failure not controlled by medication, breathing failure requiring a breathing machine, or a psychiatric condition that would prevent the person from giving informed consent
• People with currently active cancer in the brain or spinal cord, if they have a history of cancer in those areas
• People for whom a suitable, willing, closely matched related stem cell donor is already available
• People with Non-Hodgkin's lymphoma or other conditions where treatments known to be curative are still available

Important: Always verify eligibility with the trial site directly before applying.